TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›OGEN›Financials
Annual statements · SEC XBRL · FY2016 – FY2025

ORAGENICS INC (OGEN) financials

Income statement

ORAGENICS INC (OGEN) income statement, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$0.00$0.00———$87.0K$132K$37.7K——
Revenue growth——————51.2%-71.4%——
Gross profit$0.00$0.00————————
Operating income-$8.54M-$6.72M-$9.99M-$15.9M-$26.6M-$15.8M-$14.4M-$20.9M-$10.6M-$9.36M
Operating margin—————-18130.3%-10964.6%-55519.9%——
Net income-$7.01M-$6.73M-$9.91M-$15.6M-$26.4M-$15.7M-$14.3M-$20.7M-$10.6M-$9.84M
Net margin—————-18062.0%-10864.0%-54858.1%——
EPS (diluted)-$1.57-$1.37-$0.87-$0.37-$0.47-$0.14-$7.11-$9.18-$47.88-$4.56

Cash flow

ORAGENICS INC (OGEN) cash flow, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$7.08M-$6.36M-$9.08M-$13.0M-$17.0M-$13.5M-$15.2M-$7.29M-$8.60M-$9.25M
Capital expenditures$27.2K—$125K$25.2K—$43.9K$128K———
Free cash flow-$7.10M—-$9.20M-$13.0M—-$13.5M-$15.4M———

Balance sheet

ORAGENICS INC (OGEN) balance sheet, annual, from SEC filings
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$4.08M$6.17M$20.2M$18.3M$17.6M$27.3M$11.4M$3.48M$865K$4.40M
Total assets$4.31M$7.21M$22.0M$19.8M$18.7M$28.2M$14.8M$4.97M$1.47M$10.1M
Total liabilities———————$1.80M$1.68M$1.79M
Shareholders' equity$2.97M$6.32M$20.9M$17.2M$16.8M$26.5M$13.0M$3.17M-$212K$8.28M
Retained earnings-$94.7M-$101M-$111M-$127M-$154M-$171M-$186M-$206M-$217M-$227M
Shares (wtd avg diluted)4.91M4.93M29.4M46.1M91.8M1.94M2.01M2.25M221K2.16M

Every figure is extracted from ORAGENICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does OGEN pay a dividend?
ORAGENICS INC reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full OGEN analysis — verdict, score & filings →Is OGEN a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.